Caris Life Sciences, Inc. (CAI)
NASDAQ
26.27
+1.69 (+6.88%)
Closed
Aug 21, 2026
Day's Range
24.3226.60
52 wk Range
14.1942.50
Financial Statements - CAI - Caris Life Sciences, Inc.
Revenue
812.03M▲ 97.0%
Net Income
-68.08M▲ 75.8%Net Margin -8.4%
EBITDA
83.56M▲ 141.5%
Free Cash Flow
66.89M▲ 126.4%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|
| Sales | 812.03M | 412.26M | 306.12M | 294.01M | 416.54M | 432.09M |
| Cost of Goods | 272.86M | 233.47M | 216.81M | 189.17M | 312.71M | 311.35M |
| Gross Profit | 539.16M | 178.78M | 89.31M | 104.83M | 103.82M | 120.74M |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 45.11M | -257.12M | -319.55M | 77.52M | 51.12M | 70.43M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | -72.84M | 18.13M | -1.51M | 10.85M | 4.08M | 11.04M |
| Pre Tax Income | -68.08M | -281.89M | -341.41M | 82.24M | 55.21M | 81.48M |
| Income Tax | 0 | 0 | 0 | 1.80M | 4.19M | 2.88M |
| Net Income | -68.08M | -281.89M | -341.41M | 18.90M | 22.18M | 73.47M |
| EPS Basic | -3.22 | -2.7 | -1.816234 | 1.08 | 1.25 | 3.76 |
| EPS Diluted | -3.22 | -2.7 | -1.816234 | 1.06 | 1.23 | 3.71 |
| Basic Shares Outstanding | 167.20M | 254.66M | 254.66M | 17.54M | 17.73M | 19.56M |
| Diluted Shares Outstanding | 167.20M | 254.66M | 254.66M | 17.54M | 17.73M | 19.56M |
| Ebit | -11.23M | -231.86M | -309.80M | - | - | - |
| Ebitda | 83.56M | -201.43M | -260.98M | 177.96M | 160.64M | 182.19M |
| Net Income Continuous Operations | -68.08M | -281.89M | -341.41M | - | - | - |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | 85.43M | 22.06M | 121.11M | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
